Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BioNTech SE (BNTX) is a leading biotechnology business based in the US. It opened the day at $166.41 after a previous close of $161.66. During the day the price has varied from a low of $155.73 to a high of $166.79. The latest price was $156.53 (25 minute delay). BioNTech is listed on the NASDAQ and employs 2,800 staff. All prices are listed in US Dollars.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.
Its last close price was $156.53, which is 79.33% up on its pre-crash value of $32.35 and 459.04% up on the lowest point reached during the March crash when the shares fell as low as $28.00.
If you had bought $1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $5.00.
| Open | $166.41 |
|---|---|
| High | $166.79 |
| Low | $155.73 |
| Close | $156.53 |
| Previous close | $161.66 |
| Change | $-5.13 |
| Change % | -3.1733% |
| Volume | 3,261,639 |
| 52-week range | $90.29 - $464.00 |
|---|---|
| 50-day moving average | $266.50 |
| 200-day moving average | $258.98 |
| Wall St. target price | $319.41 |
| PE ratio | 6.139 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $31.93 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $156.53 from 2022-01-20
| 1 week (2022-01-13) | -22.89% |
|---|---|
| 1 month (2021-12-17) | -45.51% |
| 3 months (2021-10-19) | -40.45% |
| 6 months (2021-07-21) | -39.71% |
| 1 year (2021-01-21) | 48.47% |
|---|---|
| 2 years (2020-01-21) | 328.38% |
| 3 years (2019-01-17) | N/A |
| 5 years (2017-01-17) | N/A |
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, BioNTech shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0648. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.3 billion.
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $13.8 billion |
|---|---|
| Operating margin TTM | 74.25% |
| Gross profit TTM | $-222,037,000 |
| Return on assets TTM | 81.62% |
| Return on equity TTM | 15.55% |
| Profit margin | 54.34% |
| Book value | $35.65 |
| Market capitalisation | $47.5 billion |
TTM: trailing 12 months
We're not expecting BioNTech to pay a dividend over the next 12 months.
Over the last 12 months, BioNTech's shares have ranged in value from as little as $90.29 up to $464. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -1.3818. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Everything we know about the Credo Technology Group Holding IPO, plus information on how to buy in.
Everything we know about the Hongli Group IPO, plus information on how to buy in.
Everything we know about the Reborn Coffee IPO, plus information on how to buy in.
